Capable of differentiating into nearly any cell type, induced pluripotent stem cells (iPSCs) open new avenues for modeling disease, testing drugs, and studying human biology in a way that immortalized cell lines and animal models cannot replicate. However, generating and maintaining differentiated iPSC-derived cells can be time consuming and technically demanding, requiring expertise, quality control, and validation.
To address these challenges, BPS Bioscience offers a high-quality portfolio of ready-to-use iPSC-derived cells that combine the physiological relevance of primary human cells with the consistency and ease needed for high throughput research. Researchers can access a wide range of iPSC-derived cell types including neurons, microglia, cardiomyocytes, hepatocytes, and immune cells.
Generated by reprogramming patient-derived somatic cells with Yamanaka factors, iPSCs can differentiate into diverse cell types and serve as powerful tools for disease modeling, drug discovery, and regenerative medicine.
Credit: BPS Bioscience
This diverse offering is backed by rigorous manufacturing processes. Carefully developed using controlled differentiation protocols, these iPSC-derived cells offer high purity and consistent performance across batches, minimizing experimental variability. Their reliability makes them ideally suited for applications such as disease modeling, toxicity screening, target validation, and immunology research. Shipped cryopreserved and ready for immediate use, they eliminate the need for in-house differentiation, reducing manual labor and accelerating time to data.
For even greater experimental flexibility, BPS Bioscience’s engineered iPSC lines enable the study of specific genetic variants, reporter constructs, or knockout models in human cell contexts. These customizable tools provide a high level of precision for dissecting cellular mechanisms, testing hypotheses, or modeling complex diseases like neurodegeneration, cancer, and autoimmune disorders.
Whether used in phenotypic screens, co-culture systems, or functional assays, iPSC-derived cells empower researchers with a reliable, scalable alternative to traditional models. As translational research demands more accurate human models for understanding disease and predicting drug responses, iPSC-derived cells bring greater precision to experimental design, supporting faster, more confident decisions in therapeutic development.
